Logo image of NIVF

NEWGENIVF GROUP LTD-A (NIVF) Stock Fundamental Analysis

NASDAQ:NIVF - Nasdaq - VGG0544E1051 - Common Stock - Currency: USD

2.06  -0.35 (-14.52%)

Premarket: 2.07 +0.01 (+0.49%)

Fundamental Rating

1

Taking everything into account, NIVF scores 1 out of 10 in our fundamental rating. NIVF was compared to 109 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NIVF have multiple concerns. NIVF has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NIVF has reported negative net income.
NIVF had a negative operating cash flow in the past year.
NIVF Yearly Net Income VS EBIT VS OCF VS FCFNIVF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -1M -2M

1.2 Ratios

NIVF has a Return On Assets (-3.22%) which is in line with its industry peers.
The Return On Equity of NIVF (-4.40%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROIC N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NIVF Yearly ROA, ROE, ROICNIVF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -2 -4 -6 -8

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NIVF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NIVF Yearly Profit, Operating, Gross MarginsNIVF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for NIVF has been reduced compared to 1 year ago.
NIVF has a worse debt/assets ratio than last year.
NIVF Yearly Shares OutstandingNIVF Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M
NIVF Yearly Total Debt VS Total AssetsNIVF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M

2.2 Solvency

NIVF has an Altman-Z score of 2.03. This is not the best score and indicates that NIVF is in the grey zone with still only limited risk for bankruptcy at the moment.
NIVF's Altman-Z score of 2.03 is in line compared to the rest of the industry. NIVF outperforms 49.53% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that NIVF is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.10, NIVF is doing good in the industry, outperforming 73.83% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 2.03
ROIC/WACCN/A
WACCN/A
NIVF Yearly LT Debt VS Equity VS FCFNIVF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.02 indicates that NIVF may have some problems paying its short term obligations.
The Current ratio of NIVF (0.02) is worse than 95.33% of its industry peers.
NIVF has a Quick Ratio of 0.02. This is a bad value and indicates that NIVF is not financially healthy enough and could expect problems in meeting its short term obligations.
NIVF has a Quick ratio of 0.02. This is amonst the worse of the industry: NIVF underperforms 95.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
NIVF Yearly Current Assets VS Current LiabilitesNIVF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

NIVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -196.60%.
EPS 1Y (TTM)-196.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-346.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NIVF Yearly Revenue VS EstimatesNIVF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
NIVF Yearly EPS VS EstimatesNIVF Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NIVF. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NIVF Price Earnings VS Forward Price EarningsNIVF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NIVF Per share dataNIVF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NIVF does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEWGENIVF GROUP LTD-A

NASDAQ:NIVF (2/28/2025, 8:04:45 PM)

Premarket: 2.07 +0.01 (+0.49%)

2.06

-0.35 (-14.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.31%
Inst Owner Change11.31%
Ins Owners1.72%
Ins Owner Change0%
Market Cap27.81M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.78
P/tB 1.78
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0
BVpS1.16
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -3.22%
ROE -4.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-0.84%
ROA(5y)N/A
ROE(3y)-1.23%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z 2.03
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-196.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-346.6%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-395.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.77%
OCF growth 3YN/A
OCF growth 5YN/A